Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil

Authors

  • Natália Kehl Moreira Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil. https://orcid.org/0000-0002-1060-6482
  • Gabriela da Silva Collar Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil. https://orcid.org/0000-0003-2819-0769
  • Priscila Lamb Wink Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre - RS, Brasil. Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Porto Alegre - RS, Brasil. https://orcid.org/0000-0002-8126-2365
  • Afonso Luís Barth Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre - RS, Brasil. Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Porto Alegre - RS, Brasil. https://orcid.org/0000-0002-7969-3908
  • Juliana Caierão Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil.

Keywords:

Ceftazidime-avibactam, Enterobacterales, Carbapenemase, Resistance

Abstract

Carbapenem-resistant Enterobacterales (CRE) are a subject of global concern as limited therapeutic options are available. New combinations of β-lactams and β-lactamase inhibitors, such as ceftazidime-avibactam (CAZ-AVI), have recently been approved in Brazil for the treatment of CRE infections. Cases of resistance during treatment or even without previous CAZ-AVI use have been published and it is worrisome in scenarios where KPC-producing Gram-negative bacilli are endemic, as in Brazil. We aimed to assess CAZ-AVI susceptibility among a CRE population recovered from hospitalized patients in Southern Brazil from 2015 to 2021. CAZ-AVI minimal inhibitory concentration (MIC) was determined by antibiotic gradient strips. All the 238 evaluated KPC-producing Enterobacterales were susceptible to CAZ-AVI (MIC = 0.25 to 8 µg/mL), with seven isolates presenting borderline MICs (8 µg/mL). Considering the clinical importance of this new antibiotic in Brazil, we emphasize the importance of surveillance studies to eventually detect resistance phenotypes or even increasing CAZ-AVI MICs.

Downloads

Download data is not yet available.

Downloads

Published

2023-11-29

How to Cite

1.
Kehl Moreira N, da Silva Collar G, Lamb Wink P, Luís Barth A, Caierão J. Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil. Clin Biomed Res [Internet]. 2023 Nov. 29 [cited 2025 Jun. 24];43(3). Available from: https://seer.ufrgs.br/index.php/hcpa/article/view/128523

Issue

Vol. 43 No. 3 (2023): Clinical and Biomedical Research

Section

Brief Communication

Categories

License

Copyright (c) 2023 Natália Kehl Moreira, Gabriela da Silva Collar, Priscila Lamb Wink, Afonso Luís Barth, Juliana Caierão

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Most read articles by the same author(s)